To improve patient access by communicating the true value of pharmaceuticals to decision-makers.
The Stratenym Solution:
Targeted medical communications
WHO WE ARE
Stratenym is a specialty medical communications firm comprising a network of expert consultants. We develop evidence-based and value-driven medical and pharmacoeconomic communications to help our clients establish their products in the marketplace.
A NOTCH ABOVE
We pride ourselves on being different. We’re dedicated to providing our clients with bespoke solutions. We’re not one of the “big guys” and this works to your advantage—we’re agile, we’re responsive, and we’re committed to your success.
At Stratenym, you’re not just another client on our roster but a partner who can feel confident knowing you’re collaborating with strategic experts.
Ready to collaborate?
Complete our short form and we’ll contact you to schedule a meeting with our leadership team to discuss your needs and our capabilities.
THE STRATENYM SOLUTION
At Stratenym, we’ve assembled a network of experienced medical and pharmacoeconomic writers, editors, and strategists to ensure you have access to some of the best minds in the business.
For each project, we match you with the ideal team, providing the specific expertise needed to ensure a successful outcome.
Stratenym creates an ecosystem of dynamic interactions between our experts, you, and your team, to help you achieve your product and business goals.
Join us at ISPOR Europe 2021!
STRATENYM is proud to be a Key Supporter of the ISPOR Europe 2021 conference, taking place from November 30th to December 3rd, 2021.
View the conference program to discover sessions of interest, or register to join us and other health economics and outcomes research professionals at the virtual event.
We hope to see you there!
European Pricing & Market Strategy Expert
“An increasing challenge for drug manufacturers is budget constraints within public funding. New pricing models are providing pharmaceutical companies with flexible agreements that not only benefit both manufacturers and payers but can also speed up time to market. This is particularly relevant for highly innovative, high-cost products that can save lives.”